Jason Coloma Sells 3,993 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock

Posted by Geri Gentry on Jun 26th, 2026

Maze Therapeutics, Inc. (NASDAQ:MAZE – Get Free Report) CEO Jason Coloma sold 3,993 shares of the firm’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $26.00, for a total value of $103,818.00. Following the completion of the transaction, the chief executive officer directly owned 25,930 shares in the company, valued at $674,180. This trade represents a 13.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Maze Therapeutics Trading Up 1.3%

Shares of MAZE opened at $27.02 on Friday. Maze Therapeutics, Inc. has a 12 month low of $10.98 and a 12 month high of $53.65. The stock’s 50-day moving average is $25.64 and its two-hundred day moving average is $36.03. The company has a debt-to-equity ratio of 0.11, a current ratio of 17.88 and a quick ratio of 17.88. The stock has a market cap of $1.50 billion, a PE ratio of -10.68 and a beta of 2.26.

Maze Therapeutics (NASDAQ:MAZE – Get Free Report) last posted its earnings results on Tuesday, May 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.02). The firm had revenue of $20.00 million during the quarter. Equities analysts forecast that Maze Therapeutics, Inc. will post -2.76 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on MAZE. Wedbush upped their target price on shares of Maze Therapeutics from $43.00 to $58.00 and gave the company an “outperform” rating in a research note on Monday, March 16th. Wall Street Zen upgraded Maze Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. JPMorgan Chase & Co. boosted their price target on Maze Therapeutics from $52.00 to $58.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 31st. BTIG Research restated a “buy” rating and set a $46.00 price objective on shares of Maze Therapeutics in a research note on Wednesday, March 25th. Finally, Mizuho raised Maze Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 11th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $66.00.

View Our Latest Stock Report on MAZE

Institutional Investors Weigh In On Maze Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Royal Bank of Canada grew its stake in Maze Therapeutics by 128.3% in the fourth quarter. Royal Bank of Canada now owns 646 shares of the company’s stock worth $27,000 after purchasing an additional 363 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in Maze Therapeutics during the fourth quarter valued at approximately $39,000. Ameritas Investment Partners Inc. raised its stake in Maze Therapeutics by 82.6% during the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after buying an additional 738 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new position in Maze Therapeutics during the 4th quarter worth approximately $43,000. Finally, Russell Investments Group Ltd. lifted its holdings in Maze Therapeutics by 947.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock worth $49,000 after buying an additional 1,725 shares during the last quarter.

Maze Therapeutics Company Profile

(Get Free Report)

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.